News Releases

Servier Announces First Patients Dosed in Pivotal Phase 2 EMBLEM-1 Cohort Evaluating Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma

Servier’s VORANIGO® (vorasidenib) and TIBSOVO® (ivosidenib) Nominated for 2026 Prix Galien International Awards

Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business

Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026

Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio

Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)